Fortress Biotech, Inc. (FBIO)
FBIO Stock Price Chart
Explore Fortress Biotech, Inc. interactive price chart. Choose custom timeframes to analyze FBIO price movements and trends.
FBIO Company Profile
Discover essential business fundamentals and corporate details for Fortress Biotech, Inc. (FBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Nov 2011
Employees
101.00
Website
https://www.fortressbiotech.comCEO
Lindsay Allan Rosenwald
Description
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
FBIO Financial Timeline
Browse a chronological timeline of Fortress Biotech, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 24 Mar 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.32.
Earnings released on 14 Aug 2025
EPS came in at -$0.46 falling short of the estimated -$0.31 by -48.39%, while revenue for the quarter reached $16.41M , missing expectations by -24.63%.
Earnings released on 21 May 2025
EPS came in at -$1.03 falling short of the estimated -$0.44 by -134.09%, while revenue for the quarter reached $13.14M , beating expectations by +13.07%.
Earnings released on 27 Mar 2025
EPS came in at -$0.53 surpassing the estimated -$0.79 by +32.91%, while revenue for the quarter reached $15.12M , missing expectations by -7.22%.
Earnings released on 14 Nov 2024
EPS came in at -$0.76 falling short of the estimated -$0.27 by -181.48%, while revenue for the quarter reached $14.63M , missing expectations by -6.08%.
Earnings released on 13 Aug 2024
EPS came in at -$0.73 surpassing the estimated -$1.32 by +44.70%, while revenue for the quarter reached $14.90M , beating expectations by +0.85%.
Earnings released on 15 May 2024
EPS came in at -$1.03 surpassing the estimated -$2.03 by +49.26%, while revenue for the quarter reached $13.03M , missing expectations by -7.78%.
Earnings released on 28 Mar 2024
EPS came in at -$0.53 surpassing the estimated -$1.97 by +73.10%, while revenue for the quarter reached $19.95M , beating expectations by +33.96%.
Earnings released on 14 Nov 2023
EPS came in at -$0.94 surpassing the estimated -$3.53 by +73.37%, while revenue for the quarter reached $34.75M , beating expectations by +117.88%.
Stock split effective on 10 Oct 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2023
EPS came in at -$3.60 surpassing the estimated -$3.90 by +7.69%, while revenue for the quarter reached $17.39M , missing expectations by -0.42%.
Earnings released on 15 May 2023
EPS came in at -$3.15 falling short of the estimated -$2.85 by -10.53%, while revenue for the quarter reached $12.43M , missing expectations by -38.68%.
Earnings released on 30 Mar 2023
EPS came in at -$4.50 falling short of the estimated -$3.30 by -36.36%, while revenue for the quarter reached $16.40M , missing expectations by -25.61%.
Earnings released on 14 Nov 2022
EPS came in at -$3.75 surpassing the estimated -$4.05 by +7.41%, while revenue for the quarter reached $16.53M , missing expectations by -20.68%.
Earnings released on 11 Aug 2022
EPS came in at -$3.60 falling short of the estimated -$3.00 by -20.00%, while revenue for the quarter reached $18.89M , missing expectations by -17.08%.
Earnings released on 12 May 2022
EPS came in at -$2.70 surpassing the estimated -$4.20 by +35.71%, while revenue for the quarter reached $23.93M , beating expectations by +19.22%.
Earnings released on 28 Mar 2022
EPS came in at -$5.70 falling short of the estimated $1.50 by -480.00%, while revenue for the quarter reached $18.28M , missing expectations by -53.90%.
Earnings released on 15 Nov 2021
EPS came in at -$3.90 falling short of the estimated -$1.20 by -225.00%, while revenue for the quarter reached $21.09M , beating expectations by +7.74%.
Earnings released on 16 Aug 2021
EPS came in at -$0.60 surpassing the estimated -$2.10 by +71.43%, while revenue for the quarter reached $17.84M , missing expectations by -3.13%.
Earnings released on 16 May 2021
EPS came in at -$1.65 surpassing the estimated -$2.55 by +35.29%, while revenue for the quarter reached $11.59M , meeting expectations.
Earnings released on 31 Mar 2021
EPS came in at -$0.90 surpassing the estimated -$2.70 by +66.67%, while revenue for the quarter reached $13.75M .
Earnings released on 9 Nov 2020
EPS came in at -$3.00 surpassing the estimated -$4.20 by +28.57%, while revenue for the quarter reached $9.48M .
FBIO Stock Performance
Access detailed FBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.